Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting
services and software for pharmaceutical discovery and development,
today announced that it has released version 4.0 of its powerful MedChem
Studio™ and version 3.0 of its companion MedChem
Designer™ software.
Dr. David Miller, team leader for Discovery Cheminformatics at
Simulations Plus, said: “One of the primary new features of this version
is the ability to recognize chemical structures from images on the
screen. Sometimes called ‘optical structure recognition,’ or ‘OSR,’ this
feature makes it very simple for a user to capture structures from
documents such as web pages, PowerPoint presentations and PDF files
without having to manually draw them. Internally, we have found that
having the functionality to recognize screen images has been a valuable
time-saving tool for our scientists who frequently work with
chemistry-related documents.”
Dr. Miller continued: “In addition to OSR, we are for the first time
releasing a version of MedChem Studio with 64-bit architecture, enabling
the program to use all of the available memory on the customer’s
computer, overcoming the 2GB limit intrinsic to all 32-bit
software. Since personal computers now routinely support 8GB and more of
RAM, the 64-bit version will allow users to handle data sets of
practically unlimited size, something that is increasingly important in
the pharmaceutical sciences. In addition, this version supports using
multiple processors in the same computer for certain operations that
require extensive computations, resulting in significant time savings.”
Mr. John DiBella, vice president for marketing and sales for Simulations
Plus, added: “MedChem Studio and MedChem Designer are two of the three
elements of our ADMET
Design Suite™, which we used in our two recent NCE (new chemical
entity) molecule design projects for malaria and COX-2/COX-1 inhibitors.
Along with our ADMET
Predictor™ software for property predictions, MedChem Studio and
MedChem Designer have enabled us to design lead molecules that have had
a 100% hit rate on their targets in a fraction of the time and cost that
would normally be required. As far as we know, it is unprecedented for a
software company to take the risk of announcing beforehand that it was
going to design new molecules and have them synthesized and tested, and
then to report the results, come what may. Prototypes of these new
versions of MedChem Studio and MedChem Designer were used along with a
beta version of the recently released ADMET Predictor 7.0 in the latest COX-2/COX-1
NCE project, in which the molecules were required to show activity
for not just one target, but for two targets at the same time. We
believe these demonstrations of the capabilities of the ADMET
Design Suite speak for themselves.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug
discovery and development simulation and modeling software, which is
licensed to and used in the conduct of drug research by major
pharmaceutical, biotechnology, agrochemical, and food industry companies
worldwide. Simulations Plus, Inc., is headquartered in Southern
California and trades on the NASDAQ Capital Market under the symbol
“SLP.” For more information, visit our web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995 – With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Words like “believe,”
“expect” and “anticipate” mean that these are our best estimates as of
this writing, but that there can be no assurances that expected or
anticipated results or events will actually take place, so our actual
future results could differ significantly from those statements. Factors
that could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to
identify and close acquisitions on terms favorable to the Company, and a
sustainable market. Further information on our risk factors is contained
in our quarterly and annual reports as filed with the U.S. Securities
and Exchange Commission.
Copyright Business Wire 2014